Navigation Links
Autism changes molecular structure of the brain, UCLA study finds
Date:5/25/2011

For decades, autism researchers have faced a baffling riddle: how to unravel a disorder that leaves no known physical trace as it develops in the brain.

Now a UCLA study is the first to reveal how the disorder makes its mark at the molecular level, resulting in an autistic brain that differs dramatically in structure from a healthy one. Published May 25 in the advance online edition of Nature, the findings provide new insight into how genes and proteins go awry in autism to alter the mind.

The discovery also identifies a new line of attack for researchers, who currently face a vast array of potential fronts for tackling the neurological disease and identifying its diverse causes.

"If you randomly pick 20 people with autism, the cause of each person's disease will be unique," said principal investigator Dr. Daniel Geschwind, the Gordon and Virginia MacDonald Distinguished Chair in Human Genetics and a professor of neurology and psychiatry at the David Geffen School of Medicine at UCLA. "Yet when we examined how genes and proteins interact in autistic people's brains, we saw well-defined shared patterns. This common thread could hold the key to pinpointing the disorder's origins."

The research team, led by Geschwind, included scientists from the University of Toronto and King's College London. They compared brain tissue samples obtained after death from 19 autism patients and 17 healthy volunteers. After profiling three brain areas previously linked to autism, the group zeroed in on the cerebral cortex, the most evolved part of the human brain.

The researchers focused on gene expression how a gene's DNA sequence is copied into RNA, which directs the synthesis of cellular molecules called proteins. Each protein is assigned a specific task by the gene to perform in the cell.

By measuring gene-expression levels in the cerebral cortex, the team uncovered consistent differences in how genes in a
'/>"/>

Contact: Elaine Schmidt
eschmidt@mednet.ucla.edu
310-794-2272
University of California - Los Angeles
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. U.S. Rates of Autism, ADHD Continue to Rise: Report
2. Validating preschool programs for children with autism
3. Massachusetts Study Shows Sharp Rise in Early Autism Diagnoses
4. Sporadic mutations identified in children with autism spectrum disorders
5. Fever During Pregnancy, Diabetes and Obesity May Raise Autism Risk
6. Autism Takes an Economic Toll on Moms Job, Income: Study
7. Teen Boys With Autism at Risk of Being Bullied: Study
8. S. Korean Study Suggests Autism Rate May Be Much Higher
9. Winter Conception Tied to Raised Risk for Autism
10. Prevalence of autism in South Korea estimated at 1 in 38 children
11. New study reveals autism prevalence in South Korea estimated to be 2.6 percent or 1 in 38 children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Raleigh, NC (PRWEB) November 26, 2014 ... types of materials science can cause mesothelioma that looks ... just posted a new article on the research. ... at the Fraunhofer Institute for Toxicology and Experimental Medicine ... nanotubes. While all of the rats eventually ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 For its ... independently published The AIS Report on Blue Cross and ... WellPoint, Inc. on the varied strategies the two Blues ... improve compliance with treatments for sleep apnea, ranging from ... disorder, because it’s linked to increased rates of a ...
(Date:11/26/2014)... CA (PRWEB) November 26, 2014 With ... thousands of dollars, the prosthodontists at the Anacapa Dental Art ... for dental procedures can be daunting for some. , That ... for the procedures they offer. , “No dentist wants cost ... beautiful set of teeth,” said Dr. Mamaly Reshad, partner in ...
(Date:11/26/2014)... Sonru, the video interviewing specialist, has ... Officer and Chief Marketing Officer, in addition to the ... Jeff Jones has been appointed as Chief Operating Officer. ... role of Chief Marketing Officer. , Mr Jones is ... career includes senior roles with The Walt Disney Company ...
(Date:11/26/2014)... 2014 Call 866-997-4948 (Us-Canada Toll Free) ... the details on sales(at)researchmoz(dot)us , Researchmoz.us announces a ... market 2014" with deep study of the report on ... high blood sugar. The global glucose monitoring market has ... growing number of diabetics in the world. Their numbers ...
Breaking Medicine News(10 mins):Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5Health News:Sonru Expansion continues with appointment of new executive team and opening of new London base 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3
... LOUIS, Dec. 10 A major new study published in ... women with breast cancer would be well-served by including soyfoods ... a decreased risk of death and cancer recurrence among the ... about 11 grams of soy protein (about two servings) per ...
... ... Hospital, announces that, after a national search, the Board of Trustees of Abington Health voted ... ... John H. Durham, chairman, Board of Trustees of Abington Health and Abington Memorial Hospital, announces ...
... , WASHINGTON, Dec. 10 The Community Oncology ... the U.S. may face closing their practices if critical Medicare ... a part of health care reform. , "Current health reform ... reimbursement and substantial cuts coming in January to cancer care," ...
... discovered a signaling pathway that tuberculosis bacteria use to ... their behalf. Epithelial cells line the airways and other ... co-opt these epithelial cells into helping create tubercles: the ... the bacteria to expand their numbers and spread to ...
... Scientists at the University of Pennsylvania School of Medicine have ... knowledge that a common cancer-related molecule called Src kinase is ... work demonstrated that Src kinases are activated in human squamous ... increasing the expression of the gene Fyn, a member of ...
... , SILVER SPRING, Md., Dec. 10 The ... solution approved to replace a portion of plasma used when ... the donor plasma to be used for other purposes. , ... States, platelets, which are blood components that help with blood ...
Cached Medicine News:Health News:Major New Study Finds Soyfoods Safe and Beneficial for Women With Breast Cancer 2Health News:Abington Health Announces New President and CEO 2Health News:Abington Health Announces New President and CEO 3Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis 2Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis 3Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis 4Health News:Mechanism discovered by which body's cells encourage tuberculosis infection 2Health News:Mechanism discovered by which body's cells encourage tuberculosis infection 3Health News:New model of skin cancer provides insights on second-most common type of cancer 2Health News:FDA Approves First Additive Solution for Platelet Storage Up to 5 Days 2
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... China , Nov. 26, 2014 / -- China Nepstar Chain ... "Company"), a leading retail drugstore chain in ... operated stores, today announced the appointment of Ms. ... Officer, effective immediately. Ms.Zhang has over ... joined Nepstar in March 1999. Prior to Ms. Zhang,s ...
(Date:11/24/2014)... -- Juno Therapeutics today announced that the FDA ... JCAR015 chimeric antigen receptor product candidate.  The designation ... B-cell acute lymphoblastic leukemia and was filed by ... where Phase 1 clinical trials are currently underway. ... news for patients who may benefit from the ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
Curved shafts with serrated 1.5 mm upper and 2 mm lower jaws. Serrated cross action handle with slide lock and polished finish. Most popular size or model....
Insertion forcep used for the Hydroview lens. Manufactured in titanium....
Folding forceps used for L161U. Manufactured in titanium....
Curved shafts with 70 degree angled 3 mm tips. Flat, cross action handle with dull finish. Most popular size or model....
Medicine Products: